Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients

Aging Male

Volumn 14, Issue 1, 2011, Pages 48-52

  Aktas, Binhan Kagan ^a   Gokkaya, Cevdet Serkan ^a   Bulut, Suleyman ^a   Dinek, Mehmet ^a   Ozden, Cuneyt ^a   Memis, Ali ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

benign prostatic hyperplasia; erectile dysfunction; lower urinary tract symptoms; Metabolic syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE SEVERITY; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGE FACTORS; HEALTH STATUS INDICATORS; HEALTH SURVEYS; HUMANS; IMPOTENCE, VASCULOGENIC; MALE; MEN'S HEALTH; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TURKEY; URINARY TRACT INFECTIONS;

EID: 79751497383     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2010.529197     Document Type: Article

References (30)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
2. Hammarsten J, Hö gstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29-36. (Pubitemid 29278945)
3. Hammarsten J, Hö gstedt B, Holthuis N, Mellström D. Components of the metabolic sydrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-162. (Pubitemid 128545860)
4. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-206. (Pubitemid 44821513)
5. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-649. (Pubitemid 37542920)
6. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838-845. (Pubitemid 40745354)
7. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006;97 Suppl 2:23-28. (Pubitemid 43356992)
8. Huang WJ, Chen KK, Chang LS. Correlation between voiding and erectile function in patients with symptomatic benign prostatic hyperplasia. J Chin Med Assoc 2005;68:178-182. (Pubitemid 40528544)
9. Leungwattanakij S, Roongreungsilp U, Lertsithichai P, Ratana- Olarn KJ. The association between erectile function and severity of lower urinary tract symptoms. Med Assoc Thai 2005;88:91-95. (Pubitemid 40824418)
10. Marionneau N, Perrin P, Taieb C. Lower urinary tract symptoms are poorly correlated with erectile dysfunction. Prog Urol 2006;16:572-577. (Pubitemid 44852298)
11. Lee YC, Liu CC, Huang CN, Li WM, Wu WJ, Yeh HC, Wang CJ, Huang CH, Huang SP. The potential impact of metabolic syndrome on erectile dysfunction in aging Taiwanese males. J Sex Med 2010;7:3127-3134.
12. Demir O, Akgul K, Akar Z, Cakmak O, Ozdemir I, Bolukbasi A, Can E, Gumus BH. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009;12:29-34.
13. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obesity 2005; 29:310-316. (Pubitemid 40333230)
14. Kasturi S, Russell S, McVary KT. Metabolic syndrome and urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006;7:288-292. (Pubitemid 44623991)
15. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005;174:1327-1333. (Pubitemid 41318722)
16. Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hypreplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000;21:58-64. (Pubitemid 30069082)
17. Persson K, Pandita RK, Spitsbergen JM, Steers WD, Tuttle JB, Andersson KE. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998;275:1366-1373.
18. Hammarsten J, Hö gstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-158. (Pubitemid 32171181)
19. Park HK, Lee HW, Lee KS, Byun SS, Jeong SJ, Hong SK, Lee SE, Park JH, Lee SB, Kim KW; Korean Longitudinal Study on Health and Aging. Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology 2008;72:556-560.
20. Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S, Ponholzer A. Are lower urinary tract symptoms influenced by metabolic syndrome. Urology 2009; 73:544-548.
21. Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, Mollon P, Tamimi N, Rosen RC, McKinlay JB. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009;182:616-625.
22. Akkus E, Kadioglu A, Esen A, Doran S, Ergen A, Anafarta K, Hattat H; Turkish Erectile Dysfunction Prevalence Study Group. Prevalence and correlates of erectile dysfunction in Turkey: a population-based study. Eur Urol 2002;41:298-304. (Pubitemid 35303429)
23. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479. (Pubitemid 14026148)
24. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61. (Pubitemid 24046934)
25. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int Impot Res 2000;12:305-311. (Pubitemid 32175951)
26. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "aging male" symptoms? Results of the "Cologne Male Survey". Eur Urol 2003;44: 588-594. (Pubitemid 37336515)
27. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281: 537-544. (Pubitemid 29081307)
28. Nicolosi A, Glasser DB, Moreira ED, Villa M; Erectile Dysfunction Epidemiology Cross National Study Group. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int Impot Res 2003;15:253-257. (Pubitemid 37101658)
29. McVary KT, Siegel RL, Carlsson M. Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 2008;72:575-579.
30. Mouli S, McVary KT. PDE5 inhibitors for LUTS. Prostate Cancer Prostatic Dis 2009;12:316-324.